ATE506063T1 - Behandlung von hpv-induzierter intraepithelialer anogenitaler neoplasien - Google Patents

Behandlung von hpv-induzierter intraepithelialer anogenitaler neoplasien

Info

Publication number
ATE506063T1
ATE506063T1 AT06733077T AT06733077T ATE506063T1 AT E506063 T1 ATE506063 T1 AT E506063T1 AT 06733077 T AT06733077 T AT 06733077T AT 06733077 T AT06733077 T AT 06733077T AT E506063 T1 ATE506063 T1 AT E506063T1
Authority
AT
Austria
Prior art keywords
treatment
hpv
antigens
neoplasia
intraepithelial
Prior art date
Application number
AT06733077T
Other languages
English (en)
Inventor
Der Burg Sjoerd Van
Rienk Offringa
Cornelis Melief
Theodorus Helmerhorst
Original Assignee
Univ Leiden Medical Ct
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leiden Medical Ct filed Critical Univ Leiden Medical Ct
Application granted granted Critical
Publication of ATE506063T1 publication Critical patent/ATE506063T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT06733077T 2005-04-27 2006-04-25 Behandlung von hpv-induzierter intraepithelialer anogenitaler neoplasien ATE506063T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05103447 2005-04-27
PCT/NL2006/050099 WO2006115413A2 (en) 2005-04-27 2006-04-25 Methods and means for the treatment of hpv induced intraepithelial neoplasias

Publications (1)

Publication Number Publication Date
ATE506063T1 true ATE506063T1 (de) 2011-05-15

Family

ID=35583560

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06733077T ATE506063T1 (de) 2005-04-27 2006-04-25 Behandlung von hpv-induzierter intraepithelialer anogenitaler neoplasien

Country Status (10)

Country Link
US (2) US7807369B2 (de)
EP (2) EP2289516B1 (de)
JP (1) JP5106384B2 (de)
CN (1) CN101189014A (de)
AT (1) ATE506063T1 (de)
AU (1) AU2006240561B2 (de)
CA (1) CA2609927A1 (de)
DE (1) DE602006021408D1 (de)
ES (1) ES2363247T3 (de)
WO (1) WO2006115413A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2688589A1 (en) * 2007-05-31 2008-12-31 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Intradermal hpv peptide vaccination
EP2502985B1 (de) * 2009-11-17 2015-04-29 National University Corporation Okayama University Verfahren zur induktion der differenzierung von zahnablagerungszellen in odontoblasten
JP5559173B2 (ja) 2009-12-03 2014-07-23 株式会社アウレオ マクロファージにおけるサイトカイン産生促進組成物
US20150310128A1 (en) * 2014-04-28 2015-10-29 Elwha Llc Methods, systems, and devices for machines and machine states that manage relation data for modification of documents based on various corpora and/or modification data
WO2017015504A1 (en) * 2015-07-21 2017-01-26 Scheibel Steven Frederick Treatment and prevention of anal conditions
BR112018005200A2 (pt) 2015-09-16 2018-10-09 Dfb Soria Llc liberação de nanopartículas de fármaco e métodos de uso dos mesmos
EP3377099A4 (de) 2015-11-18 2019-07-24 ImmunoVaccine Technologies Inc. Adjuvante systeme und wasserfreie impfstoffzusammensetzung aus einem polyi:c-polynukleotidadjuvans und adjuvans auf lipidbasis
CN106632694B (zh) * 2017-01-24 2021-02-12 南京益康生物医药有限公司 一种重组蛋白及药物组合物与应用
WO2018170210A1 (en) * 2017-03-15 2018-09-20 Dfb Soria, Llc Topical therapy for the treatment of vulvar intraepithelial neoplasia (vin) and genital warts using nanoparticles of taxanes
KR102658256B1 (ko) 2017-03-15 2024-04-16 디에프비 소리아, 엘엘씨 탁산 나노입자를 사용한 피부 악성 종양의 치료용 국소 요법
RU2682783C2 (ru) * 2017-06-14 2019-03-21 Федеральное государственное бюджетное учреждение "Уральский научно-исследовательский институт охраны материнства и младенчества" Министерства здравоохранения Российской Федерации (ФГБУ "НИИ ОММ" Минздрава России) Способ лечения цервикальных интраэпителиальных неоплазий i степени, ассоциированных с впч высокого онкогенного риска, с использованием кавитированного раствора панавира
KR20200132963A (ko) 2018-03-16 2020-11-25 디에프비 소리아, 엘엘씨 탁산의 나노입자를 사용하는 자궁경부 상피내 신생물 (cin) 및 자궁경부 암의 치료를 위한 국소적 요법
CN109614613B (zh) 2018-11-30 2020-07-31 北京市商汤科技开发有限公司 图像的描述语句定位方法及装置、电子设备和存储介质
WO2022036495A1 (en) 2020-08-17 2022-02-24 Utc Therapeutics Inc. Lymphocytes-antigen presenting cells co-stimulators and uses thereof
CN111905201A (zh) * 2020-08-18 2020-11-10 珠海市索利达医疗器械有限公司 一种生殖道hr-hpv治疗设备
CN114409744B (zh) * 2022-03-29 2022-10-04 深圳吉诺因生物科技有限公司 Hpv抗原表位及其鉴定方法、应用
CN119529069B (zh) * 2025-01-22 2025-07-01 成都迈科康生物科技有限公司 一种抗hpv16和/或hpv18型e2蛋白的抗体、抗体偶联物及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2266652T3 (es) * 1997-08-05 2007-03-01 Stressgen Biotechnologies Corporation Respuestas inmunologicas contra los antigenos de hpv provocadas por compuestos que contienen un antigeno de hpv y una proteina de stress o un vector de expresion capaz de expresar dichas proteinas.
CA2361936C (en) * 1999-01-08 2009-06-16 3M Innovative Properties Company Formulations comprising imiquimod or other immune response modifiers for treating mucosal conditions
US20030118588A1 (en) * 1999-05-22 2003-06-26 Linda Diehl Induction of anti-tumor CTL immunity through in vivo triggering of 4-1BB and/or CD40
CZ20024154A3 (cs) * 2000-06-26 2003-08-13 Stressgen Biotechnologies Corporation Použití prostředku obsahujícího napojený protein pro výrobu farmaceutického přípravku pro léčení bradavic a chorob a stavů souvisejících s papiloma virem
EP1288292A1 (de) * 2001-08-31 2003-03-05 Leids Universitair Medisch Centrum Lange Peptiden die 22-40 Aminosäuren enthalten und die eine immunspezifische Immunantwort induzieren
CA2431500C (en) 2000-12-08 2016-06-07 Sjoerd Hendrikus Van Der Burg Long peptides of 22-45 amino acid residues that induce and/or enhance antigen specific immune responses
GB0105606D0 (en) * 2001-03-07 2001-04-25 Cantab Pharmaceuticals Res Ltd Immunogens and vaccines and their preparation and use
IL161978A0 (en) * 2001-12-17 2005-11-20 Zymogenetics Inc Method for treating cervical cancer
WO2005020995A1 (en) * 2003-09-02 2005-03-10 3M Innovative Properties Company Methods related to the treatment of mucosal associated conditions
WO2005077411A2 (en) * 2004-02-10 2005-08-25 Innate Pharma Composition and method for the treatment of carcinoma

Also Published As

Publication number Publication date
ES2363247T3 (es) 2011-07-28
WO2006115413A2 (en) 2006-11-02
US7807369B2 (en) 2010-10-05
JP2008539228A (ja) 2008-11-13
AU2006240561B2 (en) 2011-06-02
EP2289516A1 (de) 2011-03-02
AU2006240561A1 (en) 2006-11-02
CA2609927A1 (en) 2006-11-02
EP1874312B1 (de) 2011-04-20
JP5106384B2 (ja) 2012-12-26
WO2006115413A3 (en) 2007-04-19
DE602006021408D1 (de) 2011-06-01
US20090060870A1 (en) 2009-03-05
EP2289516B1 (de) 2014-01-08
CN101189014A (zh) 2008-05-28
US20110008287A1 (en) 2011-01-13
EP1874312A2 (de) 2008-01-09

Similar Documents

Publication Publication Date Title
ATE506063T1 (de) Behandlung von hpv-induzierter intraepithelialer anogenitaler neoplasien
EP4215543A3 (de) Hpv-spezifische bindungsmoleküle
TW200512457A (en) Method of diagnosing SARS corona virus infection
NZ590890A (en) Neutralizing anti-influenza a virus antibodies and uses thereof
RU2017132160A (ru) Антитела к pd-l1 и их применение для усиления функции t-клеток
WO2005089164A3 (en) Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
ATE466932T1 (de) Vermehrung von viren in zellkultur
MY183134A (en) Anti-cemx antibodies capable of binding to human mlge on b lymphocytes
WO2007121894A3 (en) Hpv-18-based papillomavirus vaccine
EA201291225A1 (ru) Улучшенные способы получения сквалена
EP2322931A3 (de) Verfahren zur Identifizierung von Polypeptid-targets und ihre Verwendung zur Behandlung von Immunerkrankungen
JP2018525453A5 (de)
NZ611168A (en) Monoclonal antibody recognizing human papilloma virus (hpv) l2 protein and method for measuring hpv-neutralizing antibody titer using the same
JP2015529197A5 (de)
CY1110098T1 (el) Βιομηχανικη μεθοδος για τη παρασκευη της γαμμα-λακτονης του 17-υδροξυ-6-βητα,7-βητα, 15-βητα,16-βητα-δις-μεθυλενο-3-οξο-17-αλφα πρεγκν-4-ενο-21-καρβοξυλικου οξεος και ενδιαμεσα κλειδια για την μεθοδο αυτη
Mensah et al. The human papillomavirus vaccine: current perspective and future role in prevention and treatment of anal intraepithelial neoplasia and anal cancer
WO2010056889A3 (en) Use of an antibody and a rare-earth based crystal
WO2022204713A3 (en) Antibodies to sars-cov-2
NO20070195L (no) Vaksine mot HPV16 og HPV18 og minst en annen HPV-type valgt fra HPV31, 45 eller 52
EA201171239A1 (ru) Способ детекции типа паппиломавируса человека (hpv)
ATE495243T1 (de) Verfahren zur herstellung von hochempfindlichen endonukleasen, neuartige zubereitungen von nukleasen und ihre verwendung
DE60221805D1 (de) Peptide mit affinität zu gp120, und ihre verwendungen
DE60236806D1 (de) Transkutane immunisierung gegen papillomavirus mit virusähnlichen papillomaviruspartikeln
GB2455929A (en) A method for the identification of human immunodeficiency virus related antibodies in blood
EP2593548A4 (de) Zusammensetzung aus dem menschlichen papillomavirus-antigen e7 und verwendungen davon

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties